The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Five Indian-origin women and an Indian woman have been named in Fortune’s 2025 Most Powerful Women list. The list is topped ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

Reshma Kewalramani, Bela Bajaria, Revathi Advaithi and Meena Lakdawala Flynn among women at the top of the global business ...

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals, a biotech giant best known for its cystic fibrosis drugs, took a stumble after missing Q1 2025 ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

Vertex Pharmaceuticals(NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment, with blockbuster drug Trikafta helping the company generate $11 billion in product revenue last year. The ...